Literature DB >> 1671053

The evolution of lymphadenopathy and hypergammaglobulinemia are evidence for early and sustained polyclonal B lymphocyte activation during human immunodeficiency virus infection.

D L Jacobson1, J A McCutchan, P L Spechko, I Abramson, R S Smith, A Bartok, G R Boss, D Durand, S A Bozzette, S A Spector.   

Abstract

To examine whether polyclonal activation of B lymphocytes as measured by hypergammaglobulinemia contributes to lymphadenopathy in human immunodeficiency virus (HIV) infection, correlates of adenopathy were examined in 240 homosexual men. Lymph node size was measured in 12 sites semiannually over 4 years. Both adenopathy and hyperglobulinemia developed within 1 year after seroconversion and persisted at high levels. Adenopathy declined near diagnosis of AIDS whereas serum IgG decreased 8-16 months after diagnosis. Adenopathy attributable to HIV occurred in all palpable node groups. By logistic regression, HIV-positive men were best discriminated from HIV-negative men by size of posterior cervical nodes and the number of sites with enlarged nodes. In a repeated measures model of covariance, adenopathy in HIV-positive men was associated with more CD4+ cells (P less than .002), elevated serum globulins (P less than .01), and lower platelet counts (P less than .05). Adenopathy declined over time (P less than .001) and with diagnosis of AIDS or AIDS-related complex (P less than .03). Thus, adenopathy and hypergammaglobulinemia are correlated and follow a similar course through various stages of HIV infection, suggesting that both are caused by polyclonal B cell activation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671053     DOI: 10.1093/infdis/163.2.240

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation.

Authors:  Clarisa M Buckner; Susan Moir; Jason Ho; Wei Wang; Jacqueline G Posada; Lela Kardava; Emily K Funk; Amy K Nelson; Yuxing Li; Tae-Wook Chun; Anthony S Fauci
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

2.  Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS.

Authors:  Simon Swingler; Jin Zhou; Catherine Swingler; Ann Dauphin; Thomas Greenough; Paul Jolicoeur; Mario Stevenson
Journal:  Cell Host Microbe       Date:  2008-07-17       Impact factor: 21.023

3.  Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults.

Authors:  Daniel R Feikin; Cheryl M Elie; Matthew B Goetz; Jeffrey L Lennox; George M Carlone; Sandra Romero-Steiner; Patricia F Holder; William A O'Brien; Cynthia G Whitney; Jay C Butler; Robert F Breiman
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

Review 4.  The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study.

Authors:  H Jablonowski; O Sander; R Willers; O Adams; P Bartmann; V Wahn
Journal:  Clin Investig       Date:  1994-02

5.  Feline immunodeficiency virus (FIV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management.

Authors:  M E Westman; S J Coggins; M van Dorsselaer; J M Norris; R A Squires; M Thompson; R Malik
Journal:  Aust Vet J       Date:  2022-05-16       Impact factor: 1.343

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.